Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
KAMADA LTD (KMDA)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
10/10/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Provides Corporate Update on its Israel Operations
"
08/16/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance
",
"
COMPANY'S PRESENTATION - AUGUST 2023
",
"
KAMADA LTD'S CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 (UNAUDITED)
"
08/09/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023
"
07/13/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
CURRENT REPORT
",
"
 
",
"
 
"
07/12/2023
6-K
Quarterly results
05/24/2023
SC 13D/A
DAVIDI ISHAY reports a 21.1% stake in Kamada Ltd.
05/24/2023
6-K/A
Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
05/24/2023
6-K
Quarterly results
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance
",
"
Company's Presentation – May 2023
",
"
Kamada Ltd's Consolidated Financial Statements as of March 31, 2023 (Unaudited)
"
05/24/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary
"
05/24/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds
"
05/17/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
"
05/16/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland
"
05/03/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’ s Facility in Israel
"
03/15/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Issues 2023 CEO Letter to Shareholders
",
"
Kamada 2022 Results Presentation
"
03/15/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Files Annual Report for the Year Ended December 31, 2022
"
03/15/2023
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/15/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth
"
03/09/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023
"
01/04/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’ s Facility in Israel
"
12/22/2022
6-K
Quarterly results
12/19/2022
6-K
Quarterly results
11/22/2022
6-K
Quarterly results
11/17/2022
6-K/A
Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
11/16/2022
6-K
Quarterly results
11/08/2022
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
CURRENT REPORT
",
"
 
",
"
 
"
11/07/2022
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
REPORT OF FOREIGN PRIVATE ISSUER
",
"
Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT
"
10/26/2022
6-K
Quarterly results
10/19/2022
6-K
Quarterly results
08/17/2022
6-K
Quarterly results
08/10/2022
6-K
Quarterly results
07/15/2022
6-K
Quarterly results
07/06/2022
6-K
Quarterly results
06/28/2022
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans:
06/15/2022
6-K
Quarterly results
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy